(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 27.95% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.63%.
Castle Biosciences's revenue in 2023 is $123,740,000.On average, 2 Wall Street analysts forecast CSTL's revenue for 2023 to be $4,171,981,512, with the lowest CSTL revenue forecast at $4,163,549,008, and the highest CSTL revenue forecast at $4,180,414,017.
In 2024, CSTL is forecast to generate $5,161,878,465 in revenue, with the lowest revenue forecast at $5,132,496,458 and the highest revenue forecast at $5,191,260,472.